Phase 1 study for people with Brain Cancer

Not yet recruiting Phase 1

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status Not yet recruiting
Phase Phase 1
Sponsor Olivia Newton-John Cancer Research Institute
Registry number NCT07739017
Started 1 December 2026 Today 16 October 2026 Estimated completion 1 June 2028

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
Royal Brisbane and Women's Hospital Herston QLD Status not stated
Austin Health Heidelberg VIC Status not stated

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age 18 Years to 75 Years
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 54

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

* Male or female aged ≥ 18 years at the time of signing informed consent

* Supratentorial, histologically confirmed diagnosis of primary GBM that meets the current diagnostic classification: 2021 WHO Classification of Tumors of the Central Nervous System

* KPS score ≥ 70

* Adequate organ function

* Contraception during study participation, as applicable

* Able to swallow tablets

Exclusion Criteria:

* Treatment with an investigational agent within the last 30 days excluding 5- aminolevulinic acid (5-ALA)

* Placement of Gliadel wafers or similar local therapy at time of surgery

* Receive bevacizumab

* Evidence of intracranial or intra-tumoral hemorrhage

* Significant concomitant disorder or serious intercurrent illness

* History of prior malignancy, except adequately treated non-melanoma skin cancer, carcinoma in-situ of the cervix, or disease-free for more than 5 years

* Treatment for HIV, hepatitis B, or hepatitis C

* Any gastrointestinal disorder that could result in reduced absorption of CT-179

* Any psychiatric illness or social situation that would limit compliance with study requirements

* Dose of dexamethasone higher than 4 mg/day within 1 week of the first dose of study medication

Dates on the record

Started 1 December 2026
Estimated completion 1 June 2028
Registry last updated 31 July 2026
Checked by Voxsanity 11 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 31 July 2026.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.